Healthcare

Back to Home
Browse the NKEA
Malaysia's healthcare industry has recorded strong growth over the last decade, driven primarily by local consumption of healthcare products and services.

This NKEA, led by the Ministry of Health (MOH), is focussed on growing private investments in areas such as manufacturing of pharmaceutical products and medical devices, clinical research activities and aged-care services.

HealthcareIt seeks to grow the healthcare industry and encourage collaboration between healthcare providers in the public and private sectors. The Government will also continue to provide healthcare to all Malaysians through subsidies at public hospitals and clinics. The private sector, on the other hand, has been tasked with improving access to healthcare to those who can afford to pay to help lessen the Government's burden.

By working together, the public and private sectors will be able to offer a comprehensive range of health services and products to all in Malaysia. A total of 17 Entry Point Projects (EPPs) were identifed to help meet the goals of the Healthcare NKEA. To date, 37 project owners are expected to create 26,628 new jobs and generate an income of RM6.66 billion as well as RM4.86 billion worth of new investments.

Of the 37 projects, 12 have already been completed and the rest in various stages of development, to bring the progress of Healthcare NKEA at 14.7 per cent against 181,000 jobs, 18.9 per cent against its target of 35.3 billion GNI, and 28.2 per cent against 17.2 billion investments according to the 2020 roadmap.

HealthcareSome of the existing EPPs were reviewed to better meet industry needs. For example, a mini-lab co-sponsored by the Ministry of Health, The Malaysian Organisation of Pharmaceutical Industries (MOPI) and Pharmaceutical Association of Malaysia (PhAMA) was held to revisit and revise the goal and scope of EPP 3, which focusses on the pharmaceutical sector in Malaysia. After meeting for three days, the scope of this EPP was narrowed to three streams: Generics, Bio-Pharma (Biologics and Vaccines) and Over-the-Counter (OTC) drugs.

In addition, a paper was also presented to the Cabinet in November 2013 on an outcome of the study by the International Centre of Law and Legal Studies (I-CeLLs) on Patent Law and Regime in Malaysia. The Government has agreed to review some of the recommendations of the study and make the necessary adjustments by August 2014.